trending Market Intelligence /marketintelligence/en/news-insights/trending/gupdx9ro7nbmainrhcylpw2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Amicus Therapeutics raises $250M in senior notes offering

Street Talk Episode 41 - How to Win the Funding Battle, Use Fintech to Play Offense

Forward Spark Spreads Suggest Rising Profitability Of US Renewables As Sector Matures

MA Activity The Big Story In Mature Online Video Platform Market

Martina Cheung Backs The Quality Program


Amicus Therapeutics raises $250M in senior notes offering

Amicus Therapeutics Inc. raised $250 million in a senior notes offering to refinance some of its existing debt.

The amount includes $25 million raised as a result of purchasers' decision to exercise their overallotment option.

The notes offer a 3% coupon, payable semiannually starting June 15, 2017, and are convertible into Amicus shares at an initial rate of $6.12 per share for every $1,000 principal note tendered.

The notes mature on Dec. 15, 2023, and help Amicus refinance $82.2 million of its debt. The remaining net proceeds will be used for general corporate purposes.

Goldman Sachs & Co., J.P. Morgan Securities LLC, BofA Merrill Lynch and Leerink Partners LLC acted as book runners of the offering, with Cowen and Co. acting as lead manager.